Novaliq collaborates with strong partners to ensure efficient market access and success along the Novaliq’s EyeSol® Drug Development Process.
Who is Novaliq partnering with?
- Novaliq has an European Partnership Agreement with Ursapharm, one of the leading EU ophthalmic players. In October 2015, NovaTears® entered the EU market under Ursapharm’s brand name EvoTears®. Since then, EvoTears® has been successfully launched in 8 EU countries.
- Novaliq has a strategic Licencing Partnership Agreement with AFT Pharmaceuticals Ltd (AFT), a New Zealand-based pharmaceutical company listed in ASX and NZX, for the commercialization of NovaTears® in Australia and New Zealand.
- Novaliq is also working with leading academic and industry partners including CROs, CMOs offering product development expertise and execution capabilities through pre-clinical IND, clinical development and regulatory in EU/US and Japan.